Total: 12 |
|
PMID (PMCID) | ||
---|---|---|
21453235 |
FEMALE | Middle Aged |
Hepatitis A virus-related late-onset hepatic failure: a case report. | ||
Hayashi M, Shimizu T, Tsunematsu I, Hirokawa F, Asakuma M, Takeshita A, Haga H, Tanigawa N. Exp Clin Transplant. 2011;9(2):150-2. |
||
Late-onset hepatic failure, the least of the fulminant hepatic failures, has not occurred in patients with hepatitis A virus-related acute liver failure. | ||
21453235 |
FEMALE | Middle Aged |
Hepatitis A virus-related late-onset hepatic failure: a case report. | ||
Hayashi M, Shimizu T, Tsunematsu I, Hirokawa F, Asakuma M, Takeshita A, Haga H, Tanigawa N. Exp Clin Transplant. 2011;9(2):150-2. |
||
Late-onset hepatic failure, the least of the fulminant hepatic failures, has not occurred in patients with hepatitis A virus-related acute liver failure. | ||
17636196 |
FEMALE | Adult |
A case of hemophagocytic lymphohistiocytosis after the primary Epstein-Barr virus infection. | ||
Kitazawa Y, Saito F, Nomura S, Ishii K, Kadota E. Clin Appl Thromb Hemost. 2007;13(3):323-8. |
||
The patient received intensive care, including plasma exchange for hepatic failure, extracorporeal membrane oxygenation for acute respiratory failure, and splenectomy for hemophagocytosis; however, the patient died of multiple organ failure, including fulminant hepatic failure. | ||
10347280 |
FEMALE | Infant, Newborn |
Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis. | ||
Parizhskaya M, Reyes J, Jaffe R. Pediatr Dev Pathol. 1999;2(4):360-6. |
||
Hepatic manifestations are common in hemophagocytic lymphohistiocytosis and overt hepatic failure may occur, but initial presentation as fulminant hepatic failure is not well recognized. | ||
8617425 |
MIXED_SAMPLE | Adult |
Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative). | ||
Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y. Hepatology. 1996;23(3):465-70. |
||
We examined the reasons why fulminant hepatic failure in these seven patients had not been previously attributed to ecarazine, and found that it could be explained by the following factors: (1) the time from the start of ecarazine therapy to the onset of hepatic failure was long; (2) in all cases, hepatic failure developed more than 10 days after the clinical recognition of hepatitis; and (3) characteristic signs of drug-induced hepatic failure such as a skin rash and positive lymphocytes stimulation test with the drug were absent in all cases. | ||
8617425 |
MIXED_SAMPLE | Adult |
Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative). | ||
Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y. Hepatology. 1996;23(3):465-70. |
||
We examined the reasons why fulminant hepatic failure in these seven patients had not been previously attributed to ecarazine, and found that it could be explained by the following factors: (1) the time from the start of ecarazine therapy to the onset of hepatic failure was long; (2) in all cases, hepatic failure developed more than 10 days after the clinical recognition of hepatitis; and (3) characteristic signs of drug-induced hepatic failure such as a skin rash and positive lymphocytes stimulation test with the drug were absent in all cases. | ||
8617425 |
MIXED_SAMPLE | Adult |
Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative). | ||
Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y. Hepatology. 1996;23(3):465-70. |
||
We examined the reasons why fulminant hepatic failure in these seven patients had not been previously attributed to ecarazine, and found that it could be explained by the following factors: (1) the time from the start of ecarazine therapy to the onset of hepatic failure was long; (2) in all cases, hepatic failure developed more than 10 days after the clinical recognition of hepatitis; and (3) characteristic signs of drug-induced hepatic failure such as a skin rash and positive lymphocytes stimulation test with the drug were absent in all cases. | ||
8076990 |
MIXED_SAMPLE | Child |
Wilson's disease: varied hepatic presentations. | ||
Gill HH, Shankaran K, Desai HG. Indian J Gastroenterol. 1994;13(3):95-8. |
||
Patients with Wilson's disease presented as acute viral hepatitis (n = 5), fulminant hepatic failure (n = 2), subacute hepatic failure (n = 2) and cryptogenic cirrhosis (n = 2). | ||
1871444 |
MALE | Middle Aged |
[A case of fulminant hepatic failure secondary to congestive heart failure]. | ||
Kuramoto M, Yamane T, Ueno K, Kurasawa T, Matsumoto S, Kuribayashi N. Kokyu To Junkan. 1991;39(6):607-11. |
||
The patient died of fulminant hepatic failure on the 20th days after onset of the hepatic failure. | ||
2157327 |
MALE | Infant |
Aetiology of icteric hepatitis and fulminant hepatic failure in children and the possible predisposition to hepatic failure by sickle cell disease. | ||
Yohannan MD, Arif M, Ramia S. Acta Paediatr Scand. 1990;79(2):201-5. |
||
Aetiology of icteric hepatitis and fulminant hepatic failure in children and the possible predisposition to hepatic failure by sickle cell disease. | ||
2108017 |
MALE | |
Markedly increased omega-oxidation of valproate in fulminant hepatic failure. | ||
Kuhara T, Inoue Y, Matsumoto M, Shinka T, Matsumoto I, Kawahara N, Sakura N. Epilepsia. 1990;31(2):214-7. |
||
Using gas chromatography-mass spectrometry, we showed that the urinary metabolite profile of valproate (VPA) in a subject receiving VPA and phenobarbital (PB) who died of fulminant hepatic failure was quite different from those of reported patients with Reye's syndrome or fatal hepatic failure. | ||
2204655 |
MIXED_SAMPLE | Adult |
Primary and secondary malignant disease of the liver and fulminant hepatic failure. | ||
Myszor MF, Record CO. J Clin Gastroenterol. 1990;12(4):441-6. |
||
The association and presentation of malignant disease of the liver with fulminant hepatic failure has been described sporadically, but the absence of a large series has meant that malignancy is rarely considered in the differential diagnosis of such hepatic failure. |